Moreover, a targeted delivery system of PAMAMs linked to trastuzumab was also proposed by different studies, which creates a selectivity towards HER2-positive breast cancer cells rather than other cells [21], [51], [52]. Here, ERBB2 is linked to breast carcinoma.